Drug Profile
Research programme: kidney, metabolic and cardiovascular disorder therapeutics - SCOHIA PHARMA
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class Cardiovascular therapies; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Kidney disorders; Metabolic disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Cardiovascular-disorders in Japan
- 28 Apr 2021 No recent reports of development identified for research development in Kidney-disorders in Japan
- 28 Apr 2021 No recent reports of development identified for research development in Metabolic-disorders in Japan